Metabolism in Nerve Tissue
- Nervous tissue is highly specialized and has unique metabolic needs.
- Neurons depend mainly on glucose for ATP. They have very limited glycogen stores, so they rely on a continuous blood supply. In prolonged fasting, they begin using ketone bodies as an alternative fuel, which helps spare muscle protein from being broken down for gluconeogenesis.
- ATP in neurons is mainly used to maintain ion gradients (Na⁺/K⁺ ATPase pumps), neurotransmitter synthesis, axonal transport, and vesicle release.
Synthesis and Degradation of Neurotransmitters
Acetylcholine (ACh)
Made in cholinergic neurons.
Synthesis
- Formed from Choline + Acetyl-CoA
- Enzyme: Choline Acetyltransferase
- Acetyl-CoA comes from glucose metabolism in neurons
- Choline is taken up from the synaptic cleft by active reuptake transporters
Storage & Release
- Stored in synaptic vesicles
- Released when Ca²⁺ enters the neuron during depolarization
Degradation
- Enzyme: Acetylcholinesterase (AChE) located in the synaptic cleft
- Breaks ACh into Choline + Acetate
- Choline is recycled back into the neuron
Clinical relevance
- AChE inhibitors (e.g., neostigmine, physostigmine) ↑ ACh levels
- Used in myasthenia gravis and reversal of anesthesia
- Organophosphate poisoning causes dangerous accumulation of ACh
Dopamine (DA)
Made in dopaminergic neurons in substantia nigra and ventral tegmental area.
Synthesis (Amino acid precursor: Tyrosine)
- Tyrosine → DOPA (enzyme: Tyrosine Hydroxylase, rate-limiting)
- DOPA → Dopamine (enzyme: DOPA Decarboxylase)
Cofactors
- Tyrosine hydroxylase requires BH4
- DOPA decarboxylase requires Vitamin B6 (Pyridoxal phosphate)
Storage & Release
- Stored in vesicles using VMAT transporter
- Released upon nerve stimulation
Metabolism / Inactivation
- Enzymes: MAO (monoamine oxidase) and COMT (catechol-O-methyl transferase)
- Breakdown products eventually excreted in urine as VMA and HVA
Clinical relevance
- Parkinson’s: loss of dopaminergic neurons → treat with L-DOPA
- Schizophrenia: ↑ dopamine signaling → treat with dopamine antagonists
- MAO and COMT inhibitors are used to boost dopamine in PD
GABA (Gamma Aminobutyric Acid)
Primary inhibitory neurotransmitter in the CNS.
Synthesis (from Glutamate)
- Glutamate → GABA
- Enzyme: Glutamate Decarboxylase (GAD)
- Cofactor: Vitamin B6 (Pyridoxal Phosphate)
Storage & Release
- Stored in inhibitory synaptic vesicles
- Released to hyperpolarize postsynaptic membranes via Cl⁻ influx
Degradation
- Enzyme: GABA transaminase
- End product: Succinic semialdehyde → enters TCA cycle
Clinical relevance
- B6 deficiency → ↓ GABA → seizures
- Benzodiazepines and barbiturates enhance GABAergic activity
- Vigabatrin inhibits GABA transaminase → ↑ GABA levels (used in epilepsy)